ZAGREB, Feb 26 (Hina) - Croatian pharmaceutical company "Belupo" and British-American "Smith Kline Beecham" on Thursday signed a letter of intent on future cooperation. A DM20 million-worth agreement by which "Belupo" will take a
ten-year licensed manufacturing, marketing, and distribution of "Smith Kline Beecham's" drugs for markets in Croatia, Slovenia, Bosnia-Herzegovina, and Macedonia will be signed early next month. "Belupo" won the licensing rights among numerous European pharmaceutical companies competing due to its new pharmaceutical complex being built in Koprivnica, northern Croatia, for the manufacturing of solid drugs. The sum of DM67 million has been invested in construction works, and the complex will become operational in June. The letter of intent signed today and the future licensing agreement will increase "Belupo's" 25 percent share on the domestic pharmaceutical marke
ZAGREB, Feb 26 (Hina) - Croatian pharmaceutical company "Belupo"
and British-American "Smith Kline Beecham" on Thursday signed a
letter of intent on future cooperation.
A DM20 million-worth agreement by which "Belupo" will take a ten-
year licensed manufacturing, marketing, and distribution of "Smith
Kline Beecham's" drugs for markets in Croatia, Slovenia, Bosnia-
Herzegovina, and Macedonia will be signed early next month.
"Belupo" won the licensing rights among numerous European
pharmaceutical companies competing due to its new pharmaceutical
complex being built in Koprivnica, northern Croatia, for the
manufacturing of solid drugs. The sum of DM67 million has been
invested in construction works, and the complex will become
operational in June.
The letter of intent signed today and the future licensing
agreement will increase "Belupo's" 25 percent share on the domestic
pharmaceutical market and expand its pharmaceutical programme.
(hina) ha jn